BAX vs HAE
BAX: Baxter International is a leading medical technology company delivering critical life-sustaining therapies for patients with complex medical conditions in hospitals and at home. HAE: Haemonetics provides essential technologies for blood and plasma collection, as well as specialized medical devices for hospital procedures and hemostasis management.
Side-by-side fundamentals
| Metric | BAX | HAE | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $23.90 | $119.47 | |
| Market cap | $12.4B | $5.4B | |
| P/E as of 2026-10-08 | n/a | 58.27 | |
| Net margin | -8.5% | +7.3% | HAE higher |
| Gross margin | +30.1% | +59.0% | HAE higher |
| Operating margin | -2.7% | +11.7% | HAE higher |
| ROE | -15.7% | +12.2% | HAE higher |
| ROA | -4.8% | +4.1% | HAE higher |
| Debt / equity as of 2026-09-03 | 1.52 | 1.40 | HAE lower |
| Revenue growth (YoY) as of 2026-09-03 | +5.4% | +0.4% | BAX higher |
| Revenue CAGR (3y) SEC XBRL | +3.8% | +4.5% | HAE higher |
| Dividend yield as of 2026-09-03 | +0.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 1 | 0 | BAX higher |
| Beta as of 2026-09-03 | 0.94 | 0.55 | |
| 1-year return as of 2026-10-08 close | +5.1% | +134.3% | HAE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.